Healthy high growth potential

Results

1507

Analysts expect these companies to experience strong growth in earnings over the next 3 years. They also meet criteria around being in an acceptable financial position.

1507 companies

CompanyLast Price7D Return1Y ReturnMarket CapAnalysts TargetValuationGrowthDiv YieldIndustry
AV1
AU$0.08322.1%-42.8%AU$76.9mAU$0.168.0107.8%n/aSoftware
FWRY
ج.م19.090.5%48.6%ج.م65.0bج.م22.4524.427.3%n/aDiversified Financials
AAZ
UK£3.953.3%139.4%UK£451.7mUK£5.6834.425.9%0.8%Materials
MDGL
US$507.56-5.8%49.8%US$11.1bUS$678.069.163.7%n/aPharmaceuticals & Biotech
WAYS
SEK 38.901.8%-2.3%SEK 341.1mSEK 58.00207.078.5%0%Tech
CDR
zł257.308.2%4.5%zł25.7bzł230.6149.839.0%0.4%Media
KEBNI B
SEK 1.04-1.2%-56.1%SEK 283.9mSEK 1.252.590.9%n/aTech
SAUD3
R$14.23-5.2%13.2%R$41.6bR$17.6939.530.1%5.7%Healthcare
MOD
US$201.71-3.1%43.6%US$10.4bUS$310.2974.351.3%n/aCapital Goods
6787
JP¥24,920.0035.1%233.6%JP¥565.7bJP¥28,400.0032.928.0%0.6%Tech
456A
JP¥1,330.00-0.4%n/aJP¥124.8bn/a37.623.4%n/aRetail
9218
JP¥742.000.3%6.9%JP¥7.7bn/a32.828.9%1.3%Healthcare
RHM
€1,200.8010.5%-32.1%€55.9b€1,697.8553.230.1%1.0%Capital Goods
CORT
US$109.8016.6%55.9%US$12.2bUS$135.25218.744.8%n/aPharmaceuticals & Biotech
LITE
US$849.4730.3%685.5%US$60.7bUS$1,125.93150.556.5%n/aTech
NVDA
US$211.9411.5%18.1%US$5.1tUS$302.8332.222.8%0.5%Semiconductors
CRDO
US$237.9223.7%115.7%US$40.7bUS$279.2993.927.7%n/aSemiconductors
AXSM
US$212.17-6.7%105.5%US$10.9bUS$282.3215.457.0%n/aPharmaceuticals & Biotech
2368
NT$937.0028.5%154.6%NT$453.3bNT$1,576.8841.838.2%1.1%Tech
7685
JP¥3,125.003.3%115.0%JP¥184.2bJP¥4,666.6726.325.5%0.7%Retail
4417
JP¥4,370.00-3.2%29.1%JP¥62.9bJP¥5,800.0040.826.4%1.1%Software
3711
NT$591.0018.4%307.6%NT$2.6tNT$692.7442.737.5%0.9%Semiconductors
2455
NT$388.0042.4%163.9%NT$65.3bNT$391.0094.045.2%0.7%Semiconductors
7769
NT$6,530.0026.2%319.9%NT$1.1tNT$9,210.1881.547.0%1.0%Semiconductors
Page 1 of 42
Healthy high growth potential - Investing Ideas - Simply Wall St